Tipranavir: FDA Advisory Committee will meet may 19, hear experts, public comment.
Tipranavir, made by Boehringer Ingelheim, is important because it has a different resistance profile than currently approved protease inhibitors, so those who are already resistant to the existing drugs can benefit from it. In tests so far, those who started tipranavir were more likely to control resistant virus if they also started FUZEON (enfuvirtide, T-20) at the same time, so that they had two new drugs to which they were not resistant.
The FDA meeting will be Thursday, May 19, 2005 from 8 a.m. to 5 p.m. at the Hilton Washington DC/North in Gaithersburg, Maryland, salons A, B, and C. To get to the hotel from Washington, take the Metro Red Line to Shady Grove (the end of the line), and call the hotel for a shuttle, 301-977-8900.
Public comments are scheduled from 1 to 2 p.m.; those wanting to speak should give notice by May 6. Comments can also be submitted in writing, and should be received by May 6.
Detailed background information and meeting material will be available on the FDA's Web site at least 24 hours before the meeting.
For more information see http://www.fda.gov/oc/advisory/accalendar/2000/cder 12531d051905.html
Note: For recent general information about tipranavir, see the four abstracts from the 12th Retroviruses Conference, February 2005, that mention 'tipranavir' in their title. These can be found through the abstract search at http://www.retroconference.org/Search_Abstract_2005/ Type in 'tipranavir' (without the quotation marks), make sure that 'Abstract Title' is selected, and click 'Find!'.
|Printer friendly Cite/link Email Feedback|
|Publication:||AIDS Treatment News|
|Date:||Feb 25, 2005|
|Previous Article:||HIV travel restrictions: where to find help navigating them.|
|Next Article:||Sculptra facial treatment; new physician locator.|